Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Blood

• Publication date

  2004-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2003-07-2456PMID 15001466
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel Pharmacotherapeutic Approaches to Prevention and Treatment of GVHD

  2012cited by this paper
• Impaired germinal center formation and recall T-cell-dependent immune responses in mice lacking the costimulatory ligand B7-H2.

  2003cited by this paper
• T cell costimulatory pathways: blockade for autoimmunity

  2003cited by this paper
• Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling

  2003cited by this paper
• A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells.

  2003cited by this paper
• Inducible Costimulatory Molecule-B7-Related Protein 1 Interactions Are Important for the Clonal Expansion and B Cell Helper Functions of Naive, Th1, and Th2 T Cells 1

  2003cited by this paper
• The B7–CD28 superfamily

  2002cited by this paper
• Short-circuiting long-lived humoral immunity by the heightened engagement of CD40.

  2002cited by this paper
• The Biological Outcome of CD40 Signaling Is Dependent on the Duration of CD40 Ligand Expression

  2002cited by this paper
• Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells

  2002cited by this paper
• Long-term Persistence of Anti-factor VIII Antibody-secreting Cells in Hemophilic Mice after Treatment with Human Factor VIII

  2002cited by this paper
• Single Cell Analysis of Factor VIII-specific T Cells in Hemophilic Mice after Treatment with Human Factor VIII

  2002cited by this paper
• interaction in a mouse model of hemophilia A Long-term induction of immune tolerance after blockade of CD 40-CD 40 L

  2001cited by this paper
• ICOS is critical for CD40-mediated antibody class switching

  2001cited by this paper
• Blockade of CD40/CD40 Ligand Interactions Prevents Induction of Factor VIII Inhibitors in Hemophilic Mice but Does not Induce Lasting Immune Tolerance

  2001cited by this paper
• Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A.

  2001cited by this paper
• Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.

  2001cited by this paper
• ICOS is essential for effective T-helper-cell responses

  2001cited by this paper
• ICOS co-stimulatory receptor is essential for T-cell activation and function

  2001cited by this paper
• Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors.

  2000cited by this paper
• Blockade of T Lymphocyte Costimulation with Cytotoxic T Lymphocyte–Associated Antigen 4–Immunoglobulin (Ctla4ig) Reverses the Cellular Pathology of Psoriatic Plaques, Including the Activation of Keratinocytes, Dendritic Cells, and Endothelial Cells

  2000cited by this paper
• Role of CD154 in the secondary immune response: the reduction of pre‐existing splenic germinal centers and anti‐factor VIII inhibitor titer

  2000cited by this paper
• Mouse Inducible Costimulatory Molecule (ICOS) Expression Is Enhanced by CD28 Costimulation and Regulates Differentiation of CD4+ T Cells1

  2000cited by this paper
• The CD28-related molecule ICOS is required for effective T cell-dependent immune responses.

  2000cited by this paper
• Inducible Costimulator Protein (Icos) Controls T Helper Cell Subset Polarization after Virus and Parasite Infection

  2000cited by this paper
• Characterization of Antibodies Induced by Human Factor VIII in a Murine Knockout Model of Hemophilia A

  2000cited by this paper
• Prevention and treatment of factor VIII inhibitors in murine hemophilia A.

  2000cited by this paper
• Correlation between Factor VIII Genotype and Inhibitor Development in Hemophilia A

  2000cited by this paper
• TTRAP, a Novel Protein That Associates with CD40, Tumor Necrosis Factor (TNF) Receptor-75 and TNF Receptor-associated Factors (TRAFs), and That Inhibits Nuclear Factor-κB Activation*

  2000cited by this paper
• Differential involvement of the transcription factor Blimp-1 in T cell-independent and -dependent B cell differentiation to plasma cells.

  1999cited by this paper
• Inhibitor Antibody Development and T Cell Response to Human Factor VIII in Murine Hemophilia A

  1999cited by this paper
• Phenotypic Expression of Murine Hemophilia

  1999cited by this paper
• Arrest of B lymphocyte terminal differentiation by CD40 signaling: mechanism for lack of antibody-secreting cells in germinal centers.

  1998cited by this paper
• The genetic basis of inhibitor development in haemophilia A

  1998cited by this paper
• Bidirectional regulation of human B cell responses by CD40-CD40 ligand interactions.

  1997cited by this paper
• Immune regulation by CD40 and its ligand GP39.

  1996cited by this paper
• Ligation of CD40 influences the function of human Ig-secreting B cell hybridomas both positively and negatively.

  1996cited by this paper
• Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies.

  1996cited by this paper
• Inhibitors to Coagulation Factors

  1995cited by this paper
• Generation of memory B cells and plasma cells in vitro

  1995cited by this paper
• The incidence of factor VIII inhibitors in patients with severe hemophilia A.

  1995cited by this paper
• Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A

  1995cited by this paper
• Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation

  1995cited by this paper
• CD40 cross-linking inhibits specific antibody production by human B cells.

  1995cited by this paper
• The regulation of T cell-dependent antibody formation in vitro by CD40 ligand and IL-2.

  1993cited by this paper
• Recombinant CD40 ligand stimulation of murine B cell growth and differentiation: cooperative effects of cytokines

  1993cited by this paper
• Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.

  1992cited by this paper
• Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion

  1992cited by this paper
• One out of five peripheral blood B lymphocytes is activated to high‐rate Ig production by human alloreactive T cell clones

  1983cited by this paper

• Characterization of a factor VIII/immunoglobulin heavy chain μ double-knockout mouse model of hemophilia A for long-term exposure to factor VIII proteins

  2025cites this paper
• Chemokine CXCL13 facilitates anti-FVIII inhibitory antibody development in hemophilia A patients and murine models.

  2024cites this paper
• The self-reactive FVIII T cell repertoire in healthy individuals relies on a short set of epitopes and public clonotypes

  2024cites this paper
• Differential genes expression of immune tolerance induction in hemophilia A: an exploratory RNA-seq test from a Chinese hemophilia comprehensive care centre

  2024cites this paper
• Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells.

  2022cites this paper
• Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells

  2022cites this paper
• Induction of Tolerance to Therapeutic Proteins With Antigen-Processing Independent T Cell Epitopes: Controlling Immune Responses to Biologics

  2021cites this paper
• Genetic Risk Factors for Inhibitor Development in Hemophilia A

  2021cites this paper
• Antigen-specific immunotherapy with apitopes suppresses generation of FVIII inhibitor antibodies in HLA-transgenic mice

  2021cites this paper
• Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A

  2020cites this paper
• Suppression of FVIII-Specific Memory B Cells by Chimeric BAR Receptor-Engineered Natural Regulatory T Cells

  2020cites this paper
• Tolerating Factor VIII: Recent Progress

  2020cites this paper
• Molecular Mechanisms of Inhibitor Development in Hemophilia

  2020cites this paper
• B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin

  2020cites this paper
• Prevention of the anti-factor VIII memory B-cell response by inhibition of the Bruton’s tyrosine kinase in experimental hemophilia A

  2019influential citation
• An update on the ‘danger theory’ in inhibitor development in hemophilia A

  2019cites this paper
• Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells

  2018cites this paper
• Review of immune tolerance induction in hemophilia A.

  2018cites this paper
• Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A

  2018cites this paper
• Elimination of factor VIII‐specific B cells by immunotoxins composed of a single factor VIII domain fused to Pseudomonas exotoxin A

  2018cites this paper
• Stratégies thérapeutiques contre la réponse immunitaire anti-Facteur VIII chez l'hémophile A : par modification de la structure du FVIII, par inhibition de la signalisation des lymphocytes B

  2017cites this paper
• Anti‐FcγRIIB (CD32) Antibodies Differentially Modulate Murine FVIII‐Specific Recall Response in vitro

  2017cites this paper
• anti-Fc RIIB ( CD 32 ) antibodies differentially modulate murine FVIII-specific recall response in vitro Running title : Modulation of factor VIII ( FVIII ) recall response

  2017cites this paper
• The impact of von Willebrand factor on factor VIII memory immune responses.

  2017cites this paper
• CD32 inhibition and high dose of rhFVIII suppress murine FVIII-specific recall response by distinct mechanisms in vitro

  2017influential citation
• In vivo induction of regulatory T cells for immune tolerance in hemophilia.

  2016cites this paper
• Strategies to target long-lived plasma cells for treating hemophilia A inhibitors.

  2016cites this paper
• Circulating FVIII‐specific IgG, IgA and IgM memory B cells from haemophilia A patients

  2016cites this paper
• B-cell memory against factor VIII.

  2016cites this paper
• Detection and Prediction of Factor VIII Antibody Formation in Congenital and Acquired Haemophilia A

  2016cites this paper
• Short title: Promiscuity of factor VIII

  2016cites this paper
• INHERITED BLEEDING DISORDERS FVIII inhibitors: pathogenesis and avoidance

  2015cites this paper
• Engineered antigen-speci fi c human regulatory T cells : immunosuppression of FVIII-speci fi c T-and B-cell responses

  2015cites this paper
• FVIII inhibitors: pathogenesis and avoidance.

  2015cites this paper
• Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro

  2015cites this paper
• Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.

  2015cites this paper
• The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.

  2014cites this paper
• Role of B Cells in Breaking and Maintaining Tolerance to Clotting Factor VIII in Congenital and Acquired Hemophilia A

  2014cites this paper
• Treatment Options for Acquired Hemophilia

  2014cites this paper
• Risky business of inhibitors: HLA haplotypes, gene polymorphisms, and immune responses.

  2014cites this paper
• Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice

  2014cites this paper
• Tolerance induction in hemophilia A animal models: battling inhibitors with antigen-specific immunotherapies.

  2013cites this paper
• Adjuvant facilitates tolerance induction to factor VIII in hemophilic mice through a Foxp3-independent mechanism that relies on IL-10.

  2013cites this paper
• Progress toward inducing immunologic tolerance to factor VIII.

  2013cites this paper
• Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies

  2013cites this paper
• immunoglobulin production via STAT3 inactivation and PAX5 induction Mesenchymal stromal cell derived CCL2 suppresses plasma cell

  2013cites this paper
• immunoglobulin production via STAT3 inactivation and PAX5 induction derived CCL2 suppresses plasma cell - Mesenchymal stromal cell

  2013cites this paper
• Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors

  2013cites this paper
• hemophilia A with factor VIII inhibitors High-dose factor VIII inhibits factor VIII-specific memory B cells in

  2012cites this paper
• [Current treatment of acute myeloid leukaemia in adults].

  2012cites this paper
• Anti-drug antibodies

  2012cites this paper
• hemophilic E17 HLA-DRB1*1501 mice intravenously and subcutaneously applied human FVIII in humanized T-cell epitopes associated with antibody responses after + CD4

  2012cites this paper
• is facilitated by dendritic cells together with toll-like receptor 7 agonist independent restimulation of FVIII-specific murine memory B cells - T cell

  2012cites this paper
• Inhibitory antibodies in hemophilia A

  2012cites this paper
• Les signaux de danger dans l'initiation de la réponse immunitaire contre le facteur VIII thérapeutique

  2012cites this paper
• CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice.

  2012cites this paper
• A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?

  2011cites this paper
• Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.

  2011cites this paper
• Kinetics of Humoral and Memory B Cell Response Induced by the Plasmodium falciparum 19-Kilodalton Merozoite Surface Protein 1 in Mice

  2011cites this paper
• Impact of polymorphisms in genes involved in autoimmune disease on inhibitor development in Chinese patients with haemophilia A

  2011cites this paper
• T cell-independent restimulation of FVIII-specific murine memory B cells is facilitated by dendritic cells together with toll-like receptor 7 agonist.

  2011cites this paper
• Factor VIII inhibitors: a 50‐year perspective

  2011cites this paper
• CpG-B (ODN 1826), a ligand for Toll-like receptor 9 Stimulation and inhibition of FVIII-specific memory B-cell responses by

  2011cites this paper
• Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9.

  2011cites this paper
• Endocytic receptor for pro-coagulant factor VIII: Relevance to inhibitor formation

  2010cites this paper
• High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA

  2010cites this paper
• Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells

  2010cites this paper
• Modulation of factor VIII‐specific memory B cells

  2010cites this paper
• Tolerance Induction and The Immunobiology of Factor VIII in Hemophilia A

  2010cites this paper
• Impact of polymorphisms of the major histocompatibility complex class II, interleukin‐10, tumor necrosis factor‐α and cytotoxic T‐lymphocyte antigen‐4 genes on inhibitor development in severe hemophilia A

  2009cites this paper
• B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses

  2009cites this paper
• A Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A

  2009cites this paper
• The molecular mechanisms of immunomodulation and tolerance induction to factor VIII

  2009cites this paper
• Factor VIII‐specific B cell responses in haemophilia A patients with inhibitors

  2008cites this paper
• Mesenchymal stromal cell – derived CCL 2 suppresses plasma cell immunoglobulin production via STAT 3 inactivation and PAX 5 induction

  2008cites this paper
• Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction.

  2008cites this paper
• Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice.

  2008cites this paper
• Mesenchymal Stromal Cell Derived CCL2 Suppresses Plasma Cell Immunoglobulin Production via STAT3 Inactivation and PAX5 Induction Running title: Plasmocyte Inhibition by Stromal Cells

  2008cites this paper
• FVIII Immunity: Early Events and Tolerance Mechanisms to FVIII

  2008cites this paper
• Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A.

  2008cites this paper
• Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins

  2008cites this paper
• Acute promyelocytic leukemia in patients aged 70 years and over—A single center experience of unselected patients

  2007cites this paper
• Antigen-Specific Tolerance of Human α 1-Antitrypsin Induced by Helper-Dependent Adenovirus

  2007cites this paper
• MHC-restricted B-cell antigen presentation in memory B-cell maintenance and differentiation.

  2007cites this paper
• Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors

  2007cites this paper
• Étude comparative de la réponse des lymphocytes B humains naïfs et mémoires in vitro

  2007cites this paper
• Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia

  2006cites this paper
• Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?

  2006cites this paper
• Current and future approaches to inhibitor management and aversion.

  2006cites this paper
• Tolerance to factor VIII in a transgenic mouse expressing human factor VIII cDNA carrying an Arg593 to Cys substitution

  2006cites this paper
• Overview of inhibitors.

  2006cites this paper
• Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

  2006cites this paper
• Current and Future Approaches to Inhibitor Management and Aversion

  2006cites this paper
• Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation.

  2005cites this paper
• High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.

  2005cites this paper
• Inhibitors in congenital coagulation disorders

  2004cites this paper
• Factor VIII alloantibodies in hemophilia

  2004cites this paper